表紙
市場調查報告書

NGS (次世代定序) 型監測的全球市場 分析與預測 (2019-2028年):用途·方法·種類·終端用戶·17個國家的資料·競爭情形

Global NGS-Based Monitoring and Diagnostic Test Market: Focus on Application, Method, Type, End User, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2028

出版商 BIS Research Inc. 商品編碼 909211
出版日期 內容資訊 英文 233 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
NGS (次世代定序) 型監測的全球市場 分析與預測 (2019-2028年):用途·方法·種類·終端用戶·17個國家的資料·競爭情形 Global NGS-Based Monitoring and Diagnostic Test Market: Focus on Application, Method, Type, End User, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2028
出版日期: 2019年08月21日內容資訊: 英文 233 Pages
簡介

全球NGS (次世代定序) 型監測的市場規模,預計從2019年到2028年這段期間將以18.08%的年複合成長率 (CAGR) 擴大。

本報告提供全球NGS (次世代定序) 型監測市場相關調查,提供市場概要,市場動態,各市場區隔 (用途·類型·手法·終端用戶·地區)的分析與預測,及主要企業的簡介等系統性資訊。

第1章 調查範圍·手法

第2章 市場概要

  • 簡介
  • NGS技術·應用
  • 臨床診斷的NGS方法
  • NGS技術趨勢
  • 法規·遵守

第3章 全球NGS型檢驗 (潛在市場規模·成長可能性)

  • NGS產業
  • 潛在市場·成長可能性
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 其他 (RoW)

第4章 產業考察

  • M&A
  • 產品銷售·開發
  • 相乘活性
  • 事業擴大活動·其他
  • 專利分析

第5章 市場動態

  • 概要
  • 影響分析
  • 市場成長促進因素
  • 阻礙市場成長要素
  • 市場機會

第6章 全球NGS型檢驗市場:各用途

  • 概要
  • 生殖健康
  • 癌症
  • 罕見疾病診斷
  • 心血管
  • 其他的用途

第7章 全球NGS型監測·診斷檢驗市場:各類型

  • 概要
  • 商業化驗/檢驗
  • 自體製作檢驗法 (LDT)
  • DTC (消費者直接耦合型/Direct to Consumer) 檢驗
  • 商業前檢驗

第8章 全球NGS型監測·診斷檢驗市場:各手法

  • 概要
  • 單引線定序
  • 全外顯子組測序
  • 全基因測序
  • 其他定序手法

第9章 全球NGS型監測·診斷檢驗市場:各終端用戶

  • 概要
  • 門診病人診療所/綜合診療醫生 (GP)
  • 診斷中心
  • 醫院
  • 其他終端用戶

第10章 全球NGS型監測·診斷檢驗市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他 (RoW)

第11章 競爭情形

  • 市場佔有率分析
  • 成長佔有率分析

第12章 企業簡介

  • 概要
  • Agilent Technologies, Inc.
  • Ancestry.com LLC
  • ArcherDX, Inc.
  • Beijing Genomics Institute (BGI)
  • Cancer Genetics, Inc.
  • CENTOGENE AG
  • F. Hoffmann-La Roche Ltd
  • GenePath Dx
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers, Inc.
  • Thermo Fisher Scientific Inc.
  • HTG Molecular Diagnostics, Inc.
  • Vela Diagnostics Pte. Ltd.
目錄
Product Code: BH139A

"Global NGS-Based Monitoring and Diagnostic Test Market to Grow at a CAGR of 18.08% from 2019-2028."

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global NGS based monitoring and diagnostic test market?
  • What are the underlying structures resulting in the emerging trends within the global NGS based monitoring and diagnostic test market?
  • How is each segment of the global NGS based monitoring and diagnostic test market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2028?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2028?
  • What are the key applications in the global NGS based monitoring and diagnostic test market? What are the major segments of these applications?
  • Who are the key manufacturers the global NGS based monitoring and diagnostic test, and what are their contributions?

Global NGS based Monitoring and Diagnostic Test Market Forecast, 2019-2028

The NGS based monitoring and diagnostic test Industry analysis by BIS Research projects the market to grow at a significant CAGR of 18.08% during the forecast period, 2019-2028. The NGS based monitoring and diagnostic test market generated $3,354.8 million revenue in 2018, in terms of value.

The NGS based monitoring and diagnostic test market growth has been primarily attributed to the major drivers in this market such as increasing prevalence of cancer and infectious diseases, rising number of test-based diagnostics for NGS based monitoring and diagnostic tests, steady investment and consolidation in the market and favorable regulatory environment. However, there are significant challenges which are restraining the market growth. These challenges include high cost of treatments and complexity of the treatments.

Expert Quote

"The development field has achieved huge success over the past year with regulatory approval of test in the U.S., Europe, Japan and Australia proving the potential these tests have to successfully cure patients around the globe."

Scope of the Market Intelligence on NGS Based Monitoring and Diagnostic Test Market

The NGS based monitoring and diagnostic test research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the diagnostic market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global NGS based monitoring and d9iganostic test market.

Market Segmentation

The NGS based monitoring and diagnostic test market segmentation (on the basis of manufacturing) is further segmented into application, method, type and end user.

The NGS based monitoring and diagnostic test market segmentation (on the basis of application) is segmented into reproductive health, oncology, rare disease diagnostic, cardiovascular, and other applications.

The NGS based monitoring and diagnostic test market segmentation (on the basis of method) is segmented into single read sequencing, whole exome sequencing, whole exome sequencing, and other methods.

The NGS based monitoring and diagnostic test market segmentation (on the basis of type) is segmented into commercial assay, laboratory developed tests, direct to consumer and pre commercial test.

Key Companies in the NGS Based Monitoring and Diagnostic Test Market

The key manufacturers who have been contributing significantly to the NGS Based Monitoring and Diagnostic Test market include Agilent Technologies, Inc., Ancestry.com LLC, ArcherDX, Inc.,Beijing Genomics Institute, Cancer Genetics, Inc.,Centogene AG, F. Hoffmann-La Roche Ltd, GenePath DX, illumina Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers, Inc., and Thermo Fisher Scientific Inc. among others.

Table of Contents

1. Research Scope and Methodology

  • 1.1. Scope of the Study
  • 1.2. Research Methodology
  • 1.3. Data Sources
  • 1.4. Assumptions and Limitations
  • 1.5. Data and Prediction Modeling

2. Market Overview

  • 2.1. Introduction
  • 2.2. NGS Technologies and Applications
  • 2.3. NGS Approaches in Clinical Diagnostics
  • 2.4. NGS Technology Trends
  • 2.5. Regulations and Compliances

3. Global NGS-Based Tests (Addressable Market Size and Growth Potential)

  • 3.1. NGS Industry
  • 3.2. Addressable Market and Growth Potential, 2019 and 2028
    • 3.2.1. North America
    • 3.2.2. Europe
    • 3.2.3. Asia-Pacific
    • 3.2.4. Latin America
    • 3.2.5. Rest-of-the-World

4. Industry Insights

  • 4.1. Mergers and Acquisitions
  • 4.2. Product Launches and Developments
  • 4.3. Synergistic Activities
  • 4.4. Business Expansion Activities and Others
  • 4.5. Patent Analysis
    • 4.5.1. Overview

5. Market Dynamics

  • 5.1. Overview
  • 5.2. Impact Analysis
  • 5.3. Market Drivers
    • 5.3.1. Growing Demand for Non-Invasive Diagnosis
    • 5.3.2. Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
    • 5.3.3. Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
    • 5.3.4. Technological Advancements in the Field of Computational Biology
  • 5.4. Market Restraints
    • 5.4.1. Lack of Use of Available Data for Drug Development Initiatives
    • 5.4.2. Lack of High Complexity Testing Centers
    • 5.4.3. Expensive Sequencing Procedures and Their Applications in Medical Treatments
    • 5.4.4. High Capital Requirement Hampering the Expansion of Global Reach
  • 5.5. Market Opportunities
    • 5.5.1. Massive Scope for Adoption of NGS-Based Monitoring and Diagnostic Test in Emerging Nations
    • 5.5.2. Technological Advancements in Molecular Techniques and Diagnostic Tests
    • 5.5.3. Hybridization of Technologies
    • 5.5.4. Rise of Direct-to-Consumer (DTC) Testing Services

6. Global NGS-Based Tests Market, By Application

  • 6.1. Overview
  • 6.2. Reproductive Health
    • 6.2.1. Non-Invasive Prenatal Tests
    • 6.2.2. Newborn Screening
    • 6.2.3. IVF
      • 6.2.3.1. Primary Benefits of NGS Used in IVF
  • 6.3. Oncology
  • 6.4. Rare Disease Diagnostics
  • 6.5. Cardiovascular
  • 6.6. Other Applications

7. Global NGS-Based Monitoring and Diagnostic Test Market, By Type

  • 7.1. Overview
  • 7.2. Commercial Assays/Tests
  • 7.3. Laboratory Developed Tests
  • 7.4. Direct to Consumer Test
  • 7.5. Pre-Commercial Tests

8. Global NGS-Based Monitoring and Diagnostic Test Market, By Method

  • 8.1. Overview
  • 8.2. Single Read Sequencing
  • 8.3. Whole Exome Sequencing
  • 8.4. Whole Genome Sequencing
  • 8.5. Other Sequencing Methods

9. Global NGS-Based Monitoring and Diagnostic Test Market, By End-User

  • 9.1. Overview
  • 9.2. Out-Patient Clinics/General Practitioners
  • 9.3. Diagnostic Centers
  • 9.4. Hospitals
  • 9.5. Other End Users

10. Global NGS-Based Monitoring and Diagnostic Test Market, By Region

  • 10.1. Overview
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. France
    • 10.3.3. U.K.
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Netherlands
    • 10.3.7. Russia
    • 10.3.8. Rest-of-Europe
  • 10.4. Asia-Pacific
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. Australia
    • 10.4.4. India
    • 10.4.5. South Korea
    • 10.4.6. Singapore
    • 10.4.7. Rest-of-APAC
  • 10.5. Latin America
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Rest-of-Latin America
  • 10.6. Rest-of-the-World

11. Competitive Landscape

  • 11.1. Market Share Analysis
  • 11.2. Growth Share Analysis

12. Company Profiles

  • 12.1. Overview
  • 12.2. Agilent Technologies, Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Role of Agilent Technologies, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.2.3. Financials
    • 12.2.4. Key Insights about Financial Health of the Company
    • 12.2.5. SWOT Analysis
  • 12.3. Ancestry.com LLC
    • 12.3.1. Company Overview
    • 12.3.2. Role of Ancestry.com LLC in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.3.3. SWOT Analysis
  • 12.4. ArcherDX, Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Role of ArcherDX, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.4.3. SWOT Analysis
  • 12.5. Beijing Genomics Institute (BGI)
    • 12.5.1. Company Overview
    • 12.5.2. Role of BGI in the in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.5.3. SWOT Analysis
  • 12.6 Cancer Genetics, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Role of Cancer Genetics, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.6.3. Financials
    • 12.6.4. Key Insights about Financial Health of the Company
    • 12.6.5. SWOT Analysis
  • 12.7. CENTOGENE AG
    • 12.7.1. Company Overview
    • 12.7.2. Role of CENTOGENE AG in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.7.3. SWOT Analysis
  • 12.8. F. Hoffmann-La Roche Ltd
    • 12.8.1. Company Overview
    • 12.8.2. Role of F. Hoffmann-La Roche Ltd in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.8.3. Financials
    • 12.8.4. Key Insights about Financial Health of the Company
    • 12.8.5. SWOT Analysis
  • 12.9. GenePath Dx
    • 12.9.1. Company Overview
    • 12.9.2. Role of GenePath DX, in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.9.3. SWOT Analysis
  • 12.10 Illumina, Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Role of Illumina, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.10.3. Financials
    • 12.10.4. Key Insights about Financial Health of the Company
    • 12.10.5. SWOT Analysis
  • 12.11 Laboratory Corporation of America Holdings
    • 12.11.1. Company Overview
    • 12.11.2. Role of Laboratory Corporation of America Holdings in the Global NGS-Based Monitoring and Diagnostic Market
    • 12.11.3. Financials
    • 12.11.4. SWOT Analysis
  • 12.12 Myriad Genetics, Inc.
    • 12.12.1. Company Overview
    • 12.12.2. Role of Myriad Genetics, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.12.3. Financials
    • 12.12.4. SWOT Analysis
  • 12.13 QIAGEN N.V.
    • 12.13.1. Company Overview
    • 12.13.2. Role of QIAGEN N.V. in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.13.3. Financials
    • 12.13.4. Key Insights about Financial Health of the Company
    • 12.13.5. SWOT Analysis
  • 12.14 Quest Diagnostics Incorporated
    • 12.14.1. Company Overview
    • 12.14.2. Role of Quest Diagnostics Incorporated in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.14.3. Financials
    • 12.14.4. SWOT Analysis
  • 12.15 Siemens Healthineers, Inc.
    • 12.15.1. Company Overview
    • 12.15.2. Role of Siemens Healthineers, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.15.3. Financials
    • 12.15.4. Key Insights about Financial Health of the Company
    • 12.15.5. SWOT Analysis
  • 12.16 Thermo Fisher Scientific Inc.
    • 12.16.1. Company Overview
    • 12.16.2. Role of Thermo Fisher Scientific Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
    • 12.16.3. Financials
    • 12.16.4. Key Insights about Financial Health of the Company
    • 12.16.5. SWOT Analysis
  • 12.17 HTG Molecular Diagnostics, Inc.
    • 12.17.1. Company Overview
    • 12.17.2. Role of HTG Molecular Diagnostics, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
  • 12.18 Vela Diagnostics Pte. Ltd.
    • 12.18.1. Company Overview
    • 12.18.2. Role of Vela Diagnostics Pte. Ltd. In the Global NGS-Based Monitoring and Diagnostic Test Market

List of Tables

  • Table 2.1: Regulatory Bodies
  • Table 5.1: Impact Analysis of Market Drivers
  • Table 5.2: Impact Analysis of Market Restraints

List of Figures

  • Figure 1: Impact of Market Drivers and Market Restraints on the Global NGS-Based Monitoring and Diagnostic Test Market
  • Figure 2: Global NGS-Based Monitoring and Diagnostic Test Market Snapshot, 2018 and 2028 ($Million)
  • Figure 3: Dominating Segments of the Global NGS-Based Monitoring and Diagnostic Test Market, 2018 and 2028
  • Figure 4: Global NGS-Based Monitoring and Diagnostic Test Market (by Method), 2018 and 2028
  • Figure 5: Global NGS-Based Monitoring and Diagnostic Test Market (by Application), 2018 and 2028
  • Figure 6: Global NGS-Based Monitoring and Diagnostic Test Market (by Type), 2018 and 2028
  • Figure 7: Global NGS-Based Monitoring and Diagnostic Test Market (by End User), 2018 and 2028
  • Figure 8: Global NGS-Based Monitoring and Diagnostic Test Market (by Region), 2018 and 2028
  • Figure 1.1: Global NGS-Based Monitoring and Diagnostic Test Market Segmentation
  • Figure 1.2: Global NGS-Based Monitoring and Diagnostic Test Market Research Methodology
  • Figure 1.3: Primary Research
  • Figure 1.4: Secondary Research
  • Figure 1.5: Data Triangulation
  • Figure 1.6: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 1.7: Top-Down Approach (Segment-Wise Analysis)
  • Figure 1.8: Assumptions and Limitations
  • Figure 1.9: Considered Factors for Data Prediction and Modeling
  • Figure 2.1: Different steps in Next-Generation Sequencing Technology
  • Figure 2.2: Evolution of Next-Generation Sequencers with Progress in Molecular Technologies
  • Figure 3.1: North America NGS-Based Monitoring and Diagnostic Test Addressable Market, 2019 and 2028
  • Figure 3.2: Europe NGS-Based Monitoring and Diagnostic Test Addressable Market 2019 and 2028
  • Figure 3.3: Asia-Pacific NGS-Based Monitoring and Diagnostic Test Addressable Market, 2019 and 2028
  • Figure 3.4: Latin America NGS-Based Monitoring and Diagnostic Test Addressable Market 2019 and 2028
  • Figure 4.1: Share of Key Developments and Strategies, January 2016 - June 2019
  • Figure 4.2: Product Launches Share (by Company), January 2016 - June 2019
  • Figure 4.3: Synergistic Activities Share (by Company), January 2016 - June 2019
  • Figure 4.4: Business Expansion Activities Share (by Company), January 2016 - June 2019
  • Figure 4.5: Share of Patents (by Ownership), 2016-2019
  • Figure 5.1: Number of Deaths by Top 18 Infectious Diseases, 2015
  • Figure 5.2: Number of Deaths (in Millions) by Different Forms of Cancer, 2018
  • Figure 5.3: Benefits of Multiplexing Reactions
  • Figure 6.1: Global NGS-Based Monitoring and Diagnostic Test Market (by Application)
  • Figure 6.2: Global NGS-Based Monitoring and Diagnostic Test Market (by Application), 2018 and 2028
  • Figure 6.3: Global NGS-Based Monitoring and Diagnostic Test Market (by Reproductive Health), 2018-2028
  • Figure 6.4: Global NGS-Based Monitoring and Diagnostic Test Market (by NIPT), 2018-2028
  • Figure 6.5: Global NGS-Based Monitoring and Diagnostic Test Market (by Newborn Screening), 2018-2028
  • Figure 6.6: Global NGS-Based Monitoring and Diagnostic Test Market (by IVF),2018-2028
  • Figure 6.7: Global NGS-Based Monitoring and Diagnostic Test Market (by Oncology), 2018-2028
  • Figure 6.8: Global NGS-Based Monitoring and Diagnostic Test Market (by Rare Disease Diagnostics), 2018-2028
  • Figure 6.9: Global NGS-Based Monitoring and Diagnostic Test Market (by Cardiovascular), 2018-2028
  • Figure 6.10: Global NGS-Based Monitoring and Diagnostic Test Market (by Other Applications), 2018-2028
  • Figure 7.1: Global NGS-based Monitoring and Diagnostic Test Market (by Type)
  • Figure 7.2: Global NGS-based Monitoring and Diagnostic Test Market (by Type), 2018 and 2028
  • Figure 7.3: Global NGS-Based Monitoring and Diagnostic Test Market (by Commercial Assays/Tests), 2018-2028
  • Figure 7.4: Global NGS-Based Monitoring and Diagnostic Test Market (by Laboratory Developed Test), 2018-2028
  • Figure 7.5: Global NGS-Based Monitoring and Diagnostic Test Market (by Direct to Consumer Test), 2018-2028
  • Figure 7.6: Global NGS-Based Monitoring and Diagnostic Test Market (by Pre-Commercial Tests), 2018-2028
  • Figure 8.1: Global NGS-Based Monitoring and Diagnostic Test Market (by Method)
  • Figure 8.2: Global NGS-Based Monitoring and Diagnostic Test Market (by Method), 2018 and 2028
  • Figure 8.3: Global NGS-Based Monitoring and Diagnostic Test Market (by Single Read Sequencing), 2018-2028
  • Figure 8.4: Global NGS-Based Monitoring and Diagnostic Test Market (by Whole Exome Sequencing), 2018-2028
  • Figure 8.5: Global NGS-Based Monitoring and Diagnostic Test Market (by Whole Genome Sequencing), 2018-2028
  • Figure 8.6: Global NGS-Based Monitoring and Diagnostic Test Market (by Other Sequencing Methods), 2018-2028
  • Figure 9.1: Global NGS-Based Monitoring and Diagnostic Test Market (by End User)
  • Figure 9.2: Global NGS-Based Monitoring and Diagnostic Test Market (by End User), 2018 and 2028
  • Figure 9.3: Global NGS-Based Monitoring and Diagnostic Test Market (by Out-Patient Clinics/GPs), 2018-2028
  • Figure 9.4: Global NGS-Based Monitoring and Diagnostic Test Market (by Diagnostic Centers), 2018-2028
  • Figure 9.5: Global NGS-Based Monitoring and Diagnostic Test Market (by Hospitals), 2018-2028
  • Figure 9.6: Global NGS-Based Monitoring and Diagnostic Test Market (by Other End Users), 2018-2028
  • Figure 10.1: Global NGS-Based Monitoring and Diagnostic Test Market (by Region), 2018 and 2028
  • Figure 10.2: Global NGS-Based monitoring and Diagnostic Test Market (by Region), 2018-2028
  • Figure 10.3: Global NGS-Based Monitoring and Diagnostic Test Market Share (by Region), 2018
  • Figure 10.4: Global NGS-Based Monitoring and Diagnostic Test Market Share (by Region), 2028
  • Figure 10.5: North America NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.6: North America: Market Dynamics
  • Figure 10.7: North America NGS-Based Monitoring and Diagnostic Test Market (by Country), 2018-2028
  • Figure 10.8: U.S. NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.9: Canada NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.10: Europe NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.11: Europe: Market Dynamics
  • Figure 10.12: Europe NGS-Based Monitoring and Diagnostic Test Market (by Country), 2018-2028
  • Figure 10.13: Germany NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.14: France NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.15: The U.K. NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.16: Italy NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.17: Spain NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.18: Netherlands NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.19: Russia NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.20: Rest-of-Europe NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.21: Asia-Pacific NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.22: APAC: Market Dynamics
  • Figure 10.23: APAC NGS-Based Monitoring and Diagnostic Test Market (by Country), 2018-2028
  • Figure 10.24: China NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.25: Japan NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.26: Australia NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.27: India NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.28: South Korea NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.29: Singapore NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.30: RoAPAC NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.31: Latin America NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.32: Latin America: Market Dynamics
  • Figure 10.33: Latin America NGS-Based Monitoring and Diagnostic Test Market (by Country), 2018-2028
  • Figure 10.34: Brazil NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.35: Mexico NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.36: Rest-of-Latin America NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 10.37: RoW NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
  • Figure 11.1: Market Share Analysis for the Global NGS-Based Monitoring and Diagnostic Test Market, 2018
  • Figure 11.2: Growth Share Matrix for Global NGS-Based Monitoring and Diagnostic Test Market (by Company), 2018
  • Figure 12.1: Total Number of Companies Profiled
  • Figure 12.2: Agilent Technologies, Inc.: Overall Product Portfolio
  • Figure 12.3: Agilent Technologies, Inc.: Overall Financials, 2016-2018
  • Figure 12.4: Agilent Technologies, Inc.: Revenue (by Segment), 2016-2018
  • Figure 12.5: Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
  • Figure 12.6: Agilent Technologies, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.7: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 12.8: Ancestry.com LLC: Overall Product Portfolio
  • Figure 12.9: Ancestry.com LLC: SWOT Analysis
  • Figure 12.10: Ancestry.com LLC: Overall Product Portfolio
  • Figure 12.11: ArcherDX, Inc.: SWOT Analysis
  • Figure 12.12: BGI: Overall Product Portfolio
  • Figure 12.13: BGI: SWOT Analysis
  • Figure 12.14: Product Portfolio: Cancer Genetics, Inc.
  • Figure 12.15: Cancer Genetics, Inc.: Overall Financials, 2016-2018
  • Figure 12.16: Cancer Genetics, Inc.: Revenue (by Segment), 2016-2018
  • Figure 12.17: Cancer Genetics, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.18: Cancer Genetics, Inc.: SWOT Analysis
  • Figure 12.19: CENTOGENE AG: Overall Product Portfolio
  • Figure 12.20: CENTOGENE AG: SWOT Analysis
  • Figure 12.21: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 12.22: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
  • Figure 12.23: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
  • Figure 12.24: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
  • Figure 12.25: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
  • Figure 12.26: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
  • Figure 12.27: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 12.28: GenePath DX: Overall Product Portfolio
  • Figure 12.29: GenePath DX: SWOT Analysis
  • Figure 12.30: Illumina, Inc.: Overall Product Portfolio
  • Figure 12.31: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 12.32: Illumina, Inc.: Revenue (by Segment), 2016-2018
  • Figure 12.33: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 12.34: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.35: Illumina, Inc.: SWOT Analysis
  • Figure 12.36: Laboratory Corporation of America Holdings: Overall Product Portfolio
  • Figure 12.37: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
  • Figure 12.38: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
  • Figure 12.39: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
  • Figure 12.40: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 12.41: Myriad Genetics, Inc.: Overall Product Portfolio
  • Figure 12.42: Myriad Genetics, Inc.: Overall Financials, 2016-2018
  • Figure 12.43: Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
  • Figure 12.44: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 12.45: QIAGEN N.V.: Overall Product Portfolio
  • Figure 12.46: QIAGEN N.V.: Overall Financials, 2016-2018
  • Figure 12.47: QIAGEN N.V.: Revenue (by Segment), 2016-2018
  • Figure 12.48: QIAGEN N.V.: Revenue (by Region), 2016-2018
  • Figure 12.49: QIAGEN N.V.: R&D Expenditure, 2016-2018
  • Figure 12.50: QIAGEN N.V.: SWOT Analysis
  • Figure 12.51: Product Portfolio: Quest Diagnostics Incorporated
  • Figure 12.52: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
  • Figure 12.53: Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
  • Figure 12.54: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 12.55: Siemens Healthineers, Inc.: Overall Product Portfolio
  • Figure 12.56: Siemens Healthineers, Inc.: Overall Financials, 2016-2018
  • Figure 12.57: Siemens Healthineers, Inc.: Revenue (by Segment), 2016-2018
  • Figure 12.58: Siemens Healthineers, Inc.: Revenue (by Region), 2016-2018
  • Figure 12.59: Siemens Healthineers, Inc.: R&D Expenditure, 2016-2018
  • Figure 12.60: Siemens Healthineers, Inc.: SWOT Analysis
  • Figure 12.61: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 12.62: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
  • Figure 12.63: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
  • Figure 12.64: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
  • Figure 12.65: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
  • Figure 12.66: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 12.67: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
  • Figure 12.68: Vela Diagnostic Pte. Ltd.: Overall Product Portfolio
Back to Top